PolyIC-coated Prussian blue nanoparticles as a dual-mode HIV latency reversing agent.

ABSTRACT

Aim: To investigate Prussian blue nanoparticles (PBNPs) coated with the synthetic analog of dsRNA polyinosinic-polycytidylic acid (polyIC) for their ability to function as HIV latency reversing agents. Methods: A layer-by-layer method was used to synthesize polyIC-coated PBNPs (polyIC-PBNPs). PolyIC-PBNPs were stable and monodisperse, maintained the native absorbance properties of both polyIC and PBNPs and were obtained with high nanoparticle collection yield and polyIC attachment efficiencies. Results: PolyIC-PBNPs were more effective in reactivating latent HIV than free polyIC in a cell model of HIV latency. Furthermore, polyIC-PBNPs were more effective in promoting immune activation than free polyIC in CD4 and CD8 T cells. Conclusion: PBNPs function as efficient carriers of nucleic acids to directly reverse HIV latency and enhance immune activation.

HIV is a virus that attacks and weakens the immune system. If left untreated, HIV infection leads to AIDS. To combat this, administration of antiretroviral therapy allows HIV to be controlled, and an infected individual may live a normal life. However, there is no cure for HIV because the virus persists within hidden reservoirs of latently infected cells that remain undetected by the immune system. A cure strategy currently under investigation in the field utilizes a latency reversing agent (LRA) to reactivate latent HIV with the goal of promoting a response from the immune system. To achieve this goal, this study used a nanoparticle-based method to administer LRAs. More specifically, the authors synthesized Prussian blue nanoparticles (PBNPs) coated with the LRA polyinosinic-polycytidylic acid (polyIC), a synthetic analog of dsRNA. This study demonstrates that when administered in the form of nanoparticles, polyIC-coated PBNPs generate both enhanced reactivation of HIV and immune activation when compared with free polyIC. These results indicate a promising potential for using PBNPs to deliver LRAs such as polyIC to enhance current and future HIV cure strategies.